Back to Search
Start Over
Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST-D Trial Report
- Source :
- Psychiatric research and clinical practice, vol 1, iss 2
- Publication Year :
- 2019
- Publisher :
- eScholarship, University of California, 2019.
-
Abstract
- ObjectiveIn this secondary analysis of data from the Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) study, the authors sought to determine the effectiveness of early improvement (or lack thereof) for predicting remission from depression with antidepressant therapy.MethodsThis study used data from the VAST-D study, a multisite, randomized, single-blind trial with parallel assignment to one of three medication interventions for 1,522 veterans whose major depressive disorder was unresponsive to at least one course of antidepressant treatment meeting minimal standards for dosage and duration. The authors calculated the positive predictive value (PPV) and negative predictive value (NPV) of early improvement on remission, response, or greater than minimal improvement from depression for various degrees of improvement (10%-50%) on the Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C) at 1, 2, 4, and 6weeks.ResultsThe end of week 2 of treatment was identified as the best time to evaluate early improvement. The presence of a ≥20% drop from the baseline QIDS-C score by the end of week 2 resulted in a PPV for remission of 38% and an NPV of 93% by week 12. Extending the observational window to week 6 minimally improved NPV (97%). This association did not differ across treatment groups.ConclusionsA lack of early improvement at the end of week 2 of antidepressant therapy can be used to inform clinical decisions on the likelihood of nonremission of depression during the subsequent 10weeks, even when dosage optimization is incomplete.
- Subjects :
- Early improvement
Treatment‐resistant depression
Mental Health
Depression
Clinical Research
Antidepressant response
6.1 Pharmaceuticals
Clinical Trials and Supportive Activities
Behavioral and Social Science
Evaluation of treatments and therapeutic interventions
Negative predictive value
Brain Disorders
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Psychiatric research and clinical practice, vol 1, iss 2
- Accession number :
- edsair.od.......325..263a01d1931fa38379f15ff08c3897f4